5HT2 binding sites after mianserin: comparison of loss of sites and brain levels of drug
- PMID: 3816985
- DOI: 10.1016/0014-2999(87)90151-8
5HT2 binding sites after mianserin: comparison of loss of sites and brain levels of drug
Abstract
The purpose of this study was to evaluate the role of residual drug in mediating the loss of 5HT2 binding sites after in vivo treatment with mianserin. Brain levels of mianserin were measured using a radioreceptor assay and compared with the extent of receptor loss. Peak brain levels were found within 0.5 to 1 h after dosing and the drug disappeared from brain with a half-life of 1-3 h. A dissociation was found between the levels of mianserin and the loss of binding sites. At the time of peak drug levels, the density of 5HT2 sites was not changed, while 24 h later, a significant loss of sites was evident. Although some drug-related material remained in the brain at 24 h after treatment, there was no apparent relationship between the regional distribution of residual drug and the distribution of 5HT2 binding sites. Studies with [3H]mianserin confirmed these results. Furthermore, incubation of brain slices with mianserin did not lead to a decrease in 5HT2 binding site density, consistent with the conclusion that the in vivo effects of the drug do not reflect a direct action.
Similar articles
-
Adaptation of brain 5HT2 receptors after mianserin treatment: receptor sensitivity, not receptor binding, more accurately correlates with behavior.J Pharmacol Exp Ther. 1990 Aug;254(2):484-8. J Pharmacol Exp Ther. 1990. PMID: 2166792
-
Different effects of serotonin antagonists on 3H-mianserin and 3H-ketanserin recognition sites.Life Sci. 1985 Feb 25;36(8):713-21. doi: 10.1016/0024-3205(85)90190-0. Life Sci. 1985. PMID: 2983168
-
Stereoselective blockade of central [3H]5-hydroxytryptamine binding to multiple sites (5-HT1A, 5-HT1B and 5-HT1C) by mianserin and propranolol.J Pharm Pharmacol. 1987 Aug;39(8):664-6. doi: 10.1111/j.2042-7158.1987.tb03452.x. J Pharm Pharmacol. 1987. PMID: 2888864
-
On the mode of action of imipramine: relationship between serotonergic axon terminal function and down-regulation of beta-adrenergic receptors.Neuropharmacology. 1983 Mar;22(3 Spec No):373-83. doi: 10.1016/0028-3908(83)90186-7. Neuropharmacology. 1983. PMID: 6304555 Review.
-
[Antidepressant drugs and central monoaminergic receptors].Yakubutsu Seishin Kodo. 1985 Dec;5(4):303-19. Yakubutsu Seishin Kodo. 1985. PMID: 2870595 Review. Japanese.
Cited by
-
Sertraline-induced desensitization of the serotonin 5HT-2 receptor transmembrane signaling system.Psychopharmacology (Berl). 1989;99(1):64-9. doi: 10.1007/BF00634454. Psychopharmacology (Berl). 1989. PMID: 2550988
-
Comparison of the effects of mianserin and its enantiomers and metabolites on a behavioral screen for antidepressant activity.Psychopharmacology (Berl). 1991;105(4):453-8. doi: 10.1007/BF02244363. Psychopharmacology (Berl). 1991. PMID: 1771213
-
The serotonin2 antagonist ritanserin blocks quasi-morphine withdrawal at a time when mianserin is no longer effective.Psychopharmacology (Berl). 1990;100(2):258-66. doi: 10.1007/BF02244416. Psychopharmacology (Berl). 1990. PMID: 1689501
-
Mechanisms by which the putative serotonin receptor antagonist metitepin alters nociception in mice.J Neural Transm. 1988;73(1):31-41. doi: 10.1007/BF01244620. J Neural Transm. 1988. PMID: 2969948
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources